Algorae Pharmaceuticals Limited
0.01
USD
+0.00
(+17.90%)
Algorae Pharmaceuticals Limited
OTC:LVCLF
(OTC Markets)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.- Similar Companies
- Business
- Algorae Pharmaceuticals Limited engages in AI-enabled drug discovery and development, focusing on novel compound therapies and living cell technologies. The company applies its proprietary Algorae Operating System (AlgoraeOS) to identify synergistic drug combinations and accelerate translational development across therapeutic areas. Core product candidates include AI-116, a novel combination therapy comprising cannabidiol with an off-patent pharmaceutical ingredient for dementia including Alzheimer’s disease; AI-168, a cannabinoid-based novel combination intended for cardiovascular conditions such as hypertension; and NTCELL, an alginate-coated capsule designed to target neurological disorders such as Parkinson’s disease. Algorae pursues ongoing pipeline expansion through in silico and in vitro platforms, seeking to advance clinical programs and form strategic partnerships to commercialize its therapies. The company operates primarily in New Zealand with governance and research activities anchored in Australia, and maintains a broader regulatory and commercial footprint through collaborations and licensing arrangements with regional partners to extend its reach in targeted markets. Founding year and headquarters: 2019, headquartered in Melbourne, Australia. Subsidiaries and parent relationships are leveraged to support research, development, and potential global commercialization efforts. Latest major changes include strategic licensing and supply agreements to expand the commercial footprint, including alliances with manufacturing and distribution partners to facilitate regulatory approvals, registration, and market entry in key regions. In addition, the company pursues collaborations to advance its AlgoraeOS platform, enhance data-driven drug discovery capabilities, and broaden its therapeutic portfolio through commercial partnerships and potential acquisitions or investments aligned with its growth strategy. Industry focus encompasses pharmaceutical development, AI-driven drug discovery, and life sciences research services, with target markets comprising global biopharma and contract development organizations seeking innovative, computationally guided therapeutic options.
Company News
Could quantum computing advances sink Bitcoin?
Algorae completes AI prediction phase for expanded drug combination program